Format

Send to

Choose Destination
Lancet Oncol. 2019 Nov;20(11):e637-e644. doi: 10.1016/S1470-2045(19)30531-5.

Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts.

Author information

1
RTI International India, New Delhi, India; International Agency for Research on Cancer, World Health Organization, Lyon, France.
2
International Agency for Research on Cancer, World Health Organization, Lyon, France. Electronic address: basup@iarc.fr.
3
National Institute of Epidemiology, Indian Council of Medical Research, Chennai, India.
4
Department of Health and Family Welfare, Government of Punjab, Chandigarh, India.
5
Human Services and Family Welfare Department, Government of Sikkim, Gangtok, India.
6
Delhi State Cancer Institute, Delhi, India.
7
Tata Trusts, Mumbai, India.
8
Prince Aly Khan Hospital, Mumbai, India.
9
National Institute of Cancer Prevention and Research, Indian Council of Medical Research, Noida, India.
10
National Cancer Institute, All India Institute of Medical Sciences, Jhajjar Campus, Badsa, Haryana, India; Dr B R Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
11
RTI International India, New Delhi, India.
12
Kings Clinical Trials Unit, King's College London, London, UK.
13
Department of Obstetrics & Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
14
Office of Global Affairs, Department of Health and Human Services, Washington, DC, USA.
15
Global HPV and Cervical Cancer Research and Control, National Cancer Institute, Rockville, MD, USA.
16
World Health Organization, Geneva, Switzerland.
17
King's Health Partners Integrated Cancer Centre, King's College London, London, UK.

Abstract

Efforts are being made to scale up human papillomavirus (HPV) vaccination for adolescent girls in India. Bivalent and quadrivalent HPV vaccines were licensed in the country in 2008, and a nonavalent vaccine was licensed in 2018. Demonstration projects initiated in Andhra Pradesh and Gujarat in 2009 introduced HPV vaccination in public health services in India. Following a few deaths in these projects, although subsequently deemed unrelated to vaccination, HPV vaccination in research projects was suspended. This suspension by default resulted in some participants in a trial evaluating two versus three doses receiving only one dose. Since 2016, the successful introduction of HPV vaccination in immunisation programmes in Punjab and Sikkim (with high coverage and safety), government-sponsored opportunistic vaccination in Delhi, prospects of a single dose providing protection, and future availability of an affordable Indian vaccine shows promise for future widespread implementation and evaluation of HPV vaccination in India.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center